Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 11/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15048683 | 0.87 | LPAR1 (0.77) | LPAR1MGLLLPAR3ENPP2SMN1; SMN2 | |
| SCHEMBL15061860 | 0.81 | LPAR1 (0.68) | LPAR1MGLLLPAR3ENPP2SMN1; SMN2 | |
| SCHEMBL4301352 | 0.75 | LPAR1 (0.60) | LPAR1MGLL | |
| SCHEMBL6518452 | 0.72 | LPAR1 (0.56) | LPAR1LPAR3ENPP2SMN1; SMN2 | |
| SCHEMBL27665720 | 0.72 | ALDH1A1 (0.69) | LPAR1MGLLLPAR3ENPP2SMN1; SMN2 | |
| Glycerol Phenylbutyrate SCHEMBL10102804 | 0.71 | ADRB2 (0.56) | LPAR1MGLLSMN1; SMN2 | |
| SCHEMBL23260954 | 0.70 | TSHR (0.62) | LPAR1MGLLSMN1; SMN2MAPTRXFP1 | |
| SCHEMBL15048820 | 0.70 | MGLL (0.74) | LPAR1MGLLSMN1; SMN2MAPTRXFP1 | |
| SCHEMBL10533195 | 0.70 | LPAR1 (0.55) | LPAR1LPAR3MAPTRXFP1S1PR1 | |
| SCHEMBL7692985 | 0.70 | LPAR1 (0.55) | LPAR1LPAR3MAPTRXFP1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423252-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | Trailhead Biosystems Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118591620-A | Methods and compositions for generating and maturing human forebrain neural progenitor cells into small albumin positive interneurons | 特雷尔赫德生物系统股份有限公司 | 2024-09-03 | — | — | CN | claimed |
| US-20230332103-A1 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | TRAILHEAD BIOSYSTEMS INC. | 2023-10-19 | — | — | US | claimed |
| WO-2023075913-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20250195547-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | UNIV VANDERBILT (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4423252-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | Trailhead Biosystems Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118591620-A | Methods and compositions for generating and maturing human forebrain neural progenitor cells into small albumin positive interneurons | 特雷尔赫德生物系统股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023205635-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | VANDERBILT UNIVERSITY (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230332103-A1 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | TRAILHEAD BIOSYSTEMS INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023075913-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195547-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | LPAR5, MYO3B, MYO3A | LPAR1 9/4885MGLL 172/4885LPAR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.